Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 20.78 USD -3.12% Market Closed
Market Cap: 3B USD
Have any thoughts about
Denali Therapeutics Inc?
Write Note

Denali Therapeutics Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Denali Therapeutics Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Denali Therapeutics Inc
NASDAQ:DNLI
Additional Paid In Capital
$2.7B
CAGR 3-Years
20%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Additional Paid In Capital
$21.2B
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Additional Paid In Capital
$6.9B
CAGR 3-Years
-1%
CAGR 5-Years
-2%
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Additional Paid In Capital
$12.7B
CAGR 3-Years
17%
CAGR 5-Years
24%
CAGR 10-Years
18%
No Stocks Found

Denali Therapeutics Inc
Glance View

Market Cap
3B USD
Industry
Biotechnology

In the heart of the biotech innovation hub that is California, Denali Therapeutics Inc. emerges as a promising beacon in the landscape of neurodegenerative disease treatment. Established by a team of pioneers in 2015, the company aims to combat the pressing challenge of diseases like Alzheimer's, Parkinson’s, and ALS. At the core of Denali’s mission is a sophisticated approach that intersects genetics, engineering, and clinical research. This biotech firm is not just about dreaming big; it operationalizes its vision through a science-driven methodology. Denali leverages its proprietary "Transport Vehicle" technology to enhance the delivery of therapeutic antibodies across the blood-brain barrier—a critical hurdle in treating neurological disorders. By addressing genetic underpinnings and homeostasis dysfunctions, Denali positions itself as a driver of transformative healthcare solutions. Denali's business model revolves around the development and commercialization of novel therapeutics. With a focus on high unmet needs, the company aligns its research objectives with revenue generation through strategic collaborations and partnerships. These alliances bolster Denali’s financial foundation, offering resources and expertise to hasten drug development and commercialization. Denali engages in research and licensing agreements that bring in upfront payments, milestone rewards, and future royalties. This approach not only diversifies its income streams but also mitigates risks associated with drug development intricacies. As Denali nurtures its pipeline, revenue opportunities expand, resting on the successful translation of groundbreaking science into tangible, market-ready solutions that offer hope to millions grappling with debilitating neurological conditions.

DNLI Intrinsic Value
16.81 USD
Overvaluation 19%
Intrinsic Value
Price

See Also

What is Denali Therapeutics Inc's Additional Paid In Capital?
Additional Paid In Capital
2.7B USD

Based on the financial report for Sep 30, 2024, Denali Therapeutics Inc's Additional Paid In Capital amounts to 2.7B USD.

What is Denali Therapeutics Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
28%

Over the last year, the Additional Paid In Capital growth was 29%. The average annual Additional Paid In Capital growth rates for Denali Therapeutics Inc have been 20% over the past three years , 28% over the past five years .

Back to Top